Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma : Systematic review of 42 studies published 2008-2018
MacDonald, Karen M., Kavati, Abhishek, Ortiz, Benjamin, Alhossan, Abdulaziz, Lee, Christopher S. and Abraham, Ivo. (2019). Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma : Systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology. 15(5), pp. 553-569. https://doi.org/10.1080/1744666X.2019.1574571
|Authors||MacDonald, Karen M., Kavati, Abhishek, Ortiz, Benjamin, Alhossan, Abdulaziz, Lee, Christopher S. and Abraham, Ivo|
Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies.
Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation.
Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing.
|Keywords||allergic asthma; IgE; omalizumab; real-word effectiveness; systematic review|
|Journal||Expert Review of Clinical Immunology|
|Journal citation||15 (5), pp. 553-569|
|Publisher||Taylor and Francis Ltd|
|Digital Object Identifier (DOI)||https://doi.org/10.1080/1744666X.2019.1574571|
|Open access||Published as ‘gold’ (paid) open access|
|Research or scholarly||Research|
File Access Level
|Online||14 Feb 2019|
|Publication process dates|
|Accepted||23 Jan 2019|
|Deposited||02 Sep 2021|
0views this month
0downloads this month